Similar companies
Income Statement (USD)
| Q1 '25 | QoQ | |
|---|---|---|
| Operating expense | 1M | 23.6% |
| Net Income | -1M | 23.7% |
| EBITDA | -1M | 23.8% |
Balance Sheet (USD)
| Q1 '25 | QoQ | |
|---|---|---|
| Total Assets | 4.2M | 16.6% |
| Total Liabilities | 730,000 | 42.2% |
| Total Equity | 3.4M | 8.1% |
| Shares Outstanding | 5.5M | 56.2% |
Cash Flow (USD)
| Q1 '25 | QoQ | |
|---|---|---|
| Cash from operations | -1.4M | 58.1% |
| Cash from financing | 690,000 | 89.1% |
EPS
Financial Highlights for Alzamend Neuro in Q1 '25
Operating Expenses for this period were 1M, showing a -23.6% change from the last quarter. Operating expenses cover the costs of running daily business operations. A significant increase might indicate inefficiencies or investments in growth, while a decrease could suggest cost-saving measures or potential underinvestment in key areas.
Net Income for the quarter was -1M, showing a 23.7% change from the prior quarter. Net income provides a clear picture of the company's profitability after all expenses. An increase suggests the company is becoming more profitable, while a decrease may raise concerns about the company's financial health, unless there are specific one-time costs or investments.
The company's EBITDA for the quarter was -1M, showing a 23.8% change from the previous period. EBITDA gives insight into the company's operational profitability, excluding non-operating expenses like interest and taxes. A rising EBITDA indicates strong operational performance, while a declining EBITDA may signal operational challenges or increased costs.
The company's performance remained stable this quarter with no significant positive or negative changes in the key financial metrics.
